ArticleDiscover oncology2025
Bibliometric analysis of research on cervical cancer and miRNAs from 2010 to 2024: research trends, hotspots, and prospects.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual-functional nanoplatform for simultaneous degradation of circRNAJournal of Zhejiang University. Science. B · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
background and purposeMicroRNAs (miRNAs) play critical roles in regulating the progression, metastasis, drug resistance, and HPV infection in cervical cancer. This bibliometric study aims to analyze research trends, identify major contributors, and explore emerging topics to guide future research directions and therapeutic advancements.
methodsWe systematically retrieved data from the Web of Science and PubMed databases (2010–2024). Bibliometric visualization was conducted using VOSviewer and CiteSpace software, and a total of 4034 publications were analyzed.
resultsResearch activity peaked before 2020 but showed a decline after 2021. China is the leading contributor to this field, with Tang Hehua being the most prolific author. PLOS ONE is the most active journal, and Tianjin Medical University is the most productive institution. Key terms frequently mentioned include "cervical cancer," "expression," and "invasion." Current trends emphasize clinical translation, and non-coding RNA networks are integrating nanotechnology and artificial intelligence into precision medicine applications.
conclusionThis study provides a comprehensive overview of miRNA research in cervical cancer, highlighting key participants and emerging trends. Continued exploration of the mechanisms and clinical applications of miRNAs is essential for advancing treatment strategies and improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.